Hepatitis B Virus Core Antigen (HBcAg) antibody (Alexa Fluor 488)

Catalog No. ABIN873546

Product Details

Target: Hepatitis B Virus Core Antigen (HBcAg)

Reactivity: Hepatitis B Virus (HBV), Virus

Host: Mouse

Clonality: Monoclonal

Conjugate: Alexa Fluor 488

Application: Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Cross-Reactivity: Virus

Cross-Reactivity (Details): Hepatitis B Virus

Purification: Purified by Protein G.

Immunogen: Recombinant Hepatitis B Core Antigen (rHBcAg)

Clone: 1H8

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: Hepatitis B Virus Core Antigen (HBcAg)

Alternative Name: HBcAg (HBcAg Products)

Synonyms: precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25 antibody, C antibody

Target Type: Viral Protein

Background:

Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.

Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.